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ABSTRACT
Objective To explore the relation between study
concordance, take home message, funding, and
dissemination of comparative studies assessing the
effects of influenza vaccines.
Design Systematic review without meta-analysis.
Data extraction Search of the Cochrane Library, PubMed,
Embase, and the web, without language restriction, for
any studies comparing the effects of influenza vaccines
against placebo or no intervention. Abstraction and
assessment of quality of methods were carried out.
Data synthesis We identified 259 primary studies (274
datasets). Higher quality studies were significantly more
likely to show concordance between data presented and
conclusions (odds ratio 16.35, 95% confidence interval
4.24 to 63.04) and less likely to favour effectiveness of
vaccines(0.04,0.02to0.09).Governmentfundedstudies
werelesslikelytohaveconclusionsfavouringthevaccines
(0.45, 0.26 to 0.90). A higher mean journal impact factor
was associated with complete or partial industry funding
compared with government or private funding and no
funding(differencesbetweenmeans5.04).Studysizewas
not associated with concordance, content of take home
message,funding,andstudyquality.Highercitationindex
factor was associated with partial or complete industry
funding. This was sensitive to the exclusion from the
analysis of studies with undeclared funding.
Conclusion Publication in prestigious journals is
associated with partial or total industry funding, and this
association is not explained by study quality or size.
INTRODUCTION
Healthcare workers wanting to keep up to date with
recent advances in their specialty must deal with the
quantity and quality of information sources.
12 One
study estimated that every month journals publish
7287 items (studies, letters, and editorials) relevant to
primary care. These would take physicians trained in
epidemiology 627 hours to read and appraise. Few
healthcareworkershavethetimeandskillstocarryout
in depth critical appraisal of published articles.
3 Given
the pressures of everyday work, the time available for
reading a scientific article might be as little as
22 minutes.
4
Toinformtheirconductandupdatetheirknowledge
physicians might rely on a brief (two minute) scan of
material.
56This probably includes either browsing the
abstract (the “shop window” of an article) or the
conclusions paragraph (the “take home message”),
especially those published in prestigious journals (that
is,thosewiththehighestjournalimpactfactor)thatare
most readily available or of their digests. The impact
factorwasspecificallydevelopedtofacilitateprioritisa-
tionofsubscriptionresources,allowingtargetingonthe
mostcitedjournals,consideredtobemostreadandthe
ones that publish articles of the best quality. These
journals are thus more likely to be accessible and their
content widely disseminated.
78
Methodological quality of studies is the other impor-
tant aspect. Several items, all affecting the reliability of
what presents to healthcare workers, are related in a
complex fashion. Such qualityis associated with the size
of the effects reported in a study. The lower the quality,
the greater the effect of the intervention seems.
910
Funding of meta-analyses of antihypertensive drugs
by individual pharmaceutical companies has been
shown to be inversely associated with whether data
presented supported the authors’ conclusions
(concordance)
11 and directly associated with the
probability that study conclusions did or did not
support the drugs being evaluated (take home
message).
12 The relation between the items of quality,
concordance, take home message, and funding of
single studies, however, is thought to be specific to the
context, drugs evaluated, and outcomes assessed. This
implies that generalisation of quality across study
designs, interventions, and outcomes cannot be made
on current evidence. In addition we found no studies
lookingattherelationofallthesevariableswiththatof
study dissemination and possible impact.
1314
We explored the relation between study concor-
dance, take home message, funding, and citation (as a
proxy for dissemination) in studies on influenza
vaccines by reviewing all published comparative
studies.Ourchoicewasmotivatedbytheglobalnature
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analytical studies of quality items in randomised
controlled trials or their meta-analyses (in influenza
vaccines there is an abundance of non-randomised
evidence), and by the recent publication of studies
suggesting poor quality and contradictory evidence
from field studies supporting vaccination.
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METHODS
Evidence searches
We systematically reviewed comparative studies on
influenza vaccines. We used the bibliography of
available up to date systematic reviews of influenza
vaccines to identify studies comparing the effects of
influenza vaccines with placebo or no intervention
(“primary studies”) and carried out supplementary
searches for all other comparative primary studies
published by the end of 2006 (see appendix on
bmj.com for search strategy and procedure).
Data extraction and quality assessment
We extracted primary study data in duplicate accord-
ing to a list of variables (box 1).
Two reviewers, independently unblinded to the
authors and institutions of the article, extracted data
from the studies in three phases. Firstly, they read each
studyandcompiledanabstractdescribingstudycontent.
Data presented in the study were summarised on a
computerised database based onthe Cochrane vaccines
fieldstudyregister.Thisprocessinvolvedunderstanding
thedesignandintentoftheauthorsaswellasreadingand
reconciling each part of the study. We then compared
our abstract with the authors’ presentation and
summaries of results. To classify concordance and take
home message definitions we asked whether data
presented in the study supported the authors’ conclu-
sions and then whether the conclusions did or did not
support the vaccine(s) being evaluated. We classified
take home message of all studies as supporting, neutral,
orcriticaloftheeffectsofinfluenzavaccines(box2).The
definitions were based on work carried out on study
concordance and take home message.
1112 We grouped
funding sources into government/private/unfunded or
industry/mixed, concordance into yes or no/partially/
unclear, and take home message into favourable or
mixed/unfavourable/unclear.
Finally, we assessed quality of randomised and non-
randomised studies separately. Randomised studies
were assessed according to randomisation method,
generation of the allocation sequence, allocation
concealment, blinding, and follow-up. Non-rando-
mised studies were assessed for the presence of
potential confounders with the appropriate Newcas-
tle-Ottawa scales
29 for case-control and cohort studies.
We assigned risk of bias (low, moderate, and high risk
of bias) as described by the Cochrane Handbook
30 by
design category (randomised and non-randomised).
Statistical methods
Weusedχ
2teststoassesstheassociationbetweenitems
such as quality of methods, funding sources, coher-
ence, and take home message.
Toassessthelevelofdisseminationweidentifiedthe
impact factor of the journals publishing each of the
studies in the review. A journal’s impact factor is
calculated from the number of citations in the current
year to items published in the previous two years
(numerator), divided by the number of substantive
articles and reviews published in the same two years
(the denominator). This is proposed as a proxy for
journal quality and, by implication, for quality of the
research articles in that journal.
78 The impact factor
was designed to identify journals worthy of
Box 1 Variables extracted from primary studies
Study identification
Year(s) of execution of the study (the end of the past influenza season cited in the study)
Year of publication
Study design and location
Number of arms
Comparison and type of outcome assessed within the same study (papers divided into
separate studies or datasets if they contained more than one study or comparison)
Study population
Types of influenza vaccine used
Content of influenza vaccines used
Match between content and circulating viruses in the community
Types of outcome assessed
Intervention arm size
Number of events observed in the intervention arms
Types of control
Size of control arms
Number of events observed in the control arms
Type of funder
Impact factor assigned to the journal for the year after the study was published, number of
times the articles have been cited by other sources (citation index factor), conclusions of
article (classified according to the categories reported in box 2)
Bibliography of systematic reviews on influenza vaccine and
bibliographic supplementary searches identified 12 000 citations
317 papers (338 comparative studies
datasets) considered for inclusion
259 papers (274 comparative studies/datasets) included
in review (5 papers contain two comparative studies each)
RCT: 109 papers (116 datasets)
CCT: 22 papers (22 datasets)
Prospective cohorts: 67 papers (69 datasets)
Retrospective cohorts: 46 papers (47 datasets)
Case-control studies: 20 papers and datasets
24 studies/datasets excluded for various reasons
40 comparative studies/datasets excluded because
  they were head to head
Flow of primary studies in review (RCT=randomised controlled
trial; CCT=clinical controlled trial, semi-randomised trial)
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prestige of journals
8 and their circulation.
We identified the citation index of each article (the
cumulative total of the number of times the article has
been cited in journals indexed in the ISI Web of
Sciencedatabase).Thelatestimpactfactorandcitation
indices were taken from the ISI website http://
isiwebofknowledge.com/.
We also tested the association between delay in
publication (difference between the publication date
and the date the study was completed), the journal
impact factor, or the citation index factor against the
items described above by Wilcoxon and Kruskal-
Wallis non-parametric tests (SAS/STAT 9.1, SAS,
Cary,NC).Otherstudieshavedescribedanassociation
between type of take home message and citation and
type of funder and citation.
1221-28
RESULTS
Characteristics of primary studies
The figure shows the flow of the included studies.
We included 274 comparative studies/datasets (from
259 papers) in our population. These were mostly
randomised or semi-randomised (that is, the methods of
allocation were alternation or birth date) studies (138/
274, 50%) or prospective cohort studies (69/274, 25%).
Most studies were carried out on healthy or general
populations (203/274, 74%) and were government
financed (48%). Seventy per cent of studies reported
conclusions favourable to the vaccines but only 18%
showed complete concordance between data reported
andstudyconclusions.Overhalf(56%)ofstudieswereat
high risk of bias, with only 4% being at low risk. We did
not include any vaccine registration trials.
Association between study quality and concordance, take
home message, and funding
Table 1 summarises our main findings. All compar-
isons assessing the association with study quality were
carried out after we excluded studies for which we had
insufficient data (4/274). We calculated χ
2 on the basis
of the three methodological quality categories of high,
moderate,andlowriskofbias.Wecalculatedtheχ
2for
allcomparisonsoffundingsourcesforthreecategories
(government, industry, missing). Because a high
proportionofstudieshadmissingfundinginformation
(64/274, 23%) we carried out a full sensitivity analysis
to assess robustness of observed associations by
systematically assigning studies with unclear funding
source to the other known funding categories, thus
covering all possible scenarios.
Our analysis shows the presence of a strong positive
association between methodological quality and con-
cordance between results presented and study conclu-
sions (when we aggregated studies with moderate and
high risk of bias: odds ratio 16.35, 95% confidence
interval 4.24 to 63.04). In other words, the higher the
studyquality(andthelowertheriskofbias),thehigher
theprobabilityofconcordance.Inaddition,thehigher
the probability of concordance, the lower the prob-
ability that a study’s conclusions were in favour of
vaccines’ effectiveness (0.04, 0.02 to 0.09); table 2
shows examples of discordance between results and
conclusions and take home message. We found no
association between funding source and methodologi-
cal quality (excluding studies with unknown funding:
0.74,0.19to2.84),buttherewasaninverseassociation
between conclusions in favour of the vaccines’ effec-
tiveness and government funding (0.45, 0.26 to 0.90).
Box 2 Classification of study take home message
Supportive
 The authors state the dominance of the vaccines even without supporting statistical
conclusions
 The study reports statistically significant vaccine effects compared with control
intervention(s)
 The authors report the main study end points as statistically significantly dominant
(P<0.05) compared with the control arm(s)
 Theauthorsstatethatvaccinationreducesdiseaseburdenand/ortreatmentcostsand/
or resource consumption
 Theauthorsstresstheefficacy,effectiveness,andsafetyofthevaccinescomparedwith
control intervention(s)
 The authors conclude that vaccination should be undertaken
 The authors criticise dissenters on the effects of vaccination
 Theauthorssupport atleastoneoftheproducers’orprogrammesponsors’statements
on the vaccines
Neutral
 Theauthorsconcludethatthereareinsufficientdatatoassessoneoralloftheeffectsof
the vaccines
 The authors make no recommendations but seem fairly to weigh up pros and cons of
each course of action
 The authors conclude that vaccination is cost neutral
 The authors conclude that the data presented are insufficient to answer the study
question
 The authors state that after vaccination the evidence for reduction of disease burden
and/or treatment costs and/or resource consumption is slight or non-existent
 The authors dissent from at least one of the producers’ or programme sponsors’
statements on the vaccines but do not reach a definite conclusion
 Theauthorsconcludethattheevidenceshowsefficacy,effectiveness,andsafetyofthe
vaccines compared with control intervention(s) for some outcomes but not for others
 Theauthorsconcludethattheevidenceshowsefficacy,effectiveness,andsafetyofone
type of vaccine compared with another and with control intervention(s)
Critical/not supportive
 The authors report no statistically significant efficacy or effectiveness results and/or
significant harms
 The authors clearly state the vaccines’ inferiority and present data showing significant
vaccine inferiority compared with control(s)
 The authors state that vaccination does not reduce disease burden and/or treatment
costs and/or resource consumption
 Theauthorsemphasiseconcernsoverefficacyand/oreffectivenessand/orsafetyand/
or recommend alternative interventions to control the burden of disease
 The authors criticise those supporting influenza vaccination or state that vaccination
should not be introduced or continued
 Theauthorsarecriticalofalltheproducers’or programme sponsors’statementsonthe
vaccines
Fromvarious sources.
1221-28
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between funding source and type of study
conclusions.
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Association between study quality items, funding, and
dissemination
Statistical tests show no evidence of association
between the mean time lapsed from the end of the
study to the date of publication (publication delay),
methodological quality, type of study design, concor-
dance, coherence, and funder. There was no evidence
of association between either journal impact factor or
citationindexfactorand studydesign,methodological
quality, and concordance.
The mean journal impact factor of 92 government
funded studies was 3.74, and their mean citation index
factorwas33.75.Wecalculatedthemeanimpactfactor
on 114 studies, as the oldest studies were published in
Table 1 |Summary of main findings of assessment of possible association between methodological quality, concordance between data presented and
conclusions reported, take home message of article conclusions, and funding source in comparative studies of influenza vaccines
Is there a relation between: Odds ratio (95% CI) Interpretation Sensitivity analysis carriedout? If yes whatwere the results?
Methodologicalqualityandconcordance
between data presented and
conclusions reported?
Aggregate moderate and high risk of
bias: 16.35 (4.24 to 63.04)
Positive association between low risk of
bias and concordance
No
Methodological quality and funding
source?
Aggregate moderate and high risk of
bias, excluding studies with missing
funding source: 0.74 (0.19 to 2.84)
No evidence of negative association
between governmental funding source
and low risk of bias
Yes. Sensitivity analysis carried out on 240 possible scenarios:
1.64%ofscenarioswithOR<1significant,65.4%withOR<1non-
significant; 0.83% with OR=1; and 32.1% with OR >1 non-
significant at 5% level
Methodological quality and take home
message?
Aggregate moderate and high risk of
bias: 0.19 (0.05 to 0.64)
Negative association between low risk of
bias and favourable conclusion
No
Concordance between data presented
andconclusionsreportedandtakehome
message?
0.04 (0.02 to 0.09) Negative association between presence
of concordance and favourable
conclusion
No
Concordance between data presented
and conclusions reported and funding
source?
Excluding studies with missing
funding source: 1.47 (0.72 to 3.07)
No evidence of positive association
between concordance and government
funding source at 5% significance level
Yes. Sensitivity analysis carried out on 413 possible scenarios;
16.5% of scenarios with OR <1 and non-significant, 57.9% with
OR >1 non-significant, and 25.7% with OR >1 significant at 5%
level
Fundingsourceandtakehomemessage? Excluding studies with missing
funding source: 0.45 (0.26 to 0.90)
Evidenceofnegativeassociationbetween
favourable conclusion and government
funding
Yes. Sensitivity analysis carried out on 989 possible scenarios;
47.0%ofscenarioswithOR<1significant,38.5%withOR<1non-
significant, 14.4% with OR >1 non-significant, and only 0.1%
(one scenario) with OR >1 significant at 5% level
Table 2 |Examples of discrepancy between results and conclusions
Study Summary of results Author’s conclusions and reviewer comments
Wongsurakiat 2004
31
(randomised placebo
controlled trial in 125
adults and older people
with COPD)
Significant reduction shown for total acute respiratory infections (ARI) with
laboratory confirmation of influenza (RR 0.24, 95% CI 0.06 to 0.7; P=0.005)
and influenza like illness (ILI) (0.34, 0.1 to 0.99, P=0.03). For acute
exacerbations, difference not significant (0.92, 0.67 to 1.3, P=0.6). In this
category 13/21 confirmed cases of influenza isolated, so, as for total ARI
episodes (124 in vaccinated and 145 in placebo group), there was no
differencebetweentwointerventiongroups.Thisappliesalsoto“probabilityof
not being admitted to hospital related to ARI (P=0.2 by log rank test) and
probabilityofnotreceivingmechanicalventilationrelatedtoARI(P=0.4bylog
rank test)”
Study was conducted over one year. Conclusions support recommendation of
annual vaccination (one dose is sufficient in adults, as strong response has been
observed). Authors note that vaccine effectiveness has been shown, even if it was
possibly administered too late (in region where study was carried out peak
incidenceofinfluenzaoccursusuallyinMay).Comment:thoughauthorsstatethat
effectiveness is shown for influenza related ARI only, and not influenza, they
recommendvaccinationforpatientswithCOPD.Thismeansrecommendingvaccine
thoughitisnoteffectiveagainstinfluenzaandacuteexacerbations.Inaddition,lack
ofcommentoncommunityviralcirculationandvaccinecontentandmatchingmake
verification of effectiveness against ARI impossible
Wilde 1999
32
(randomised trials on
264 healthy healthcare
workers, three
consecutive seasons)
Influenzainfection(fourfoldincreaseinhaemagglutinationinhibitingantibody
against virus A or B between serum sample after immunisation and after
epidemic). Efficacy against A (H3N2) virus estimated as 88% (47% to 97%,
P=0.001);againstBvirusas89%(14%to99%,P=0.02).Authors’conclusions
about efficacy derived from cumulative data only. They apply effect measure
and significance test (χ
2) to cumulative data only. When applied to single
comparisons, significance reached only for influenza A in 1992-3 (P=0.026).
Dayswithrespiratoryillness(52v73days;P=0.57;mean0.29(SD0.68)daysv
0.41(SD1.0)days,andabsenceduetoillness(18v38days;P=0.41,mean0.1
(SD0.35)daysv0.21(SD0.75)daysnodifferentamongvaccinatedandcontrol
group (three seasons’ cumulative data)
“In conclusion, influenza vaccine is effective in preventing serologically proven
influenza infection in young, healthy hospital-based healthcare professionals and
may reduce cumulative days of illness and absence. These data suggest that a
policy of annual immunization with influenza vaccine in healthcare professionals
will reduce influenza infections and can reduce associated illness.” Comment:
influenzavaccinationisrecommendedthoughoutcomesareexclusivelyserological
(surrogates)calculatedinaggregateoverthreeyears(180ininterventionarmsand
179inthreedifferentcontrolarms).Clinicaloutcomesarenotsignificantlyaffected
by vaccination
Carman 2000
33 (block
randomised trial, 20 long
term care hospitals)
All cause mortality less common in long term care where vaccination was
offered (vaccination rate 13.6%; 102/749) than in those where it was not
(vaccination rate 22.4%; 154/688). Crude OR 0.58, 0.40 to 0.84, P=0.014).
Significance disappears after adjustment for degree of disability by Barthel
scale, age, sex, vaccination of patients (0.61, 0.36 to 1.04, P=0.092).
Virologicalsurveillance(routine,fromsomesymptomaticsubjects,fromsome
samples taken at death) did not show different frequency of viruses A or B
isolates between two groups (culture and PCR)
“Vaccination of health-care workers was associated with a substantial decrease in
mortality[forallcauses]amongpatients.However,virologicalsurveillanceshowed
no associated decrease in non-fatal influenza infection in patients.” Comment:
implausible conclusion with use of all cause mortality an outcome lacking
specificity. Long list of confounders: biased reporting of autopsy sampling,
trenchant conclusion despite apparent lack of effect on viral circulation, brief
description of vaccine content or matching (in discussion), attrition in serology
follow-up, possible selection bias of healthcare workers and patients, higher
Barthelscoreinvaccinatedarm.OncedatawereadjustedforBarthelscore,age,and
sex no effect was observed
RCT=randomised controlled trial, COPD=chronic obstructive pulmonary disease, RR=relative risk, OR=odds ratio, PCR=polymerase chain reaction.
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the 52 studies wholly or partly funded by industry, the
mean impact factor was 8.78 and the mean citation
index factor was 58.39. We calculated the mean
citation index for 74 studies as the oldest studies were
published in journals for which no citation index was
available.
Non-parametric testing shows that the impact factor
score of studies with complete or partial industry
funding was significantly higher than that of studies
funded by government and other funders (table 3).
Non-parametric testing for article citation index
showed a similar significant difference, which was,
however, sensitive to the exclusion of studies with no
declared funding source. In this case we found no
differenceincitationbetweenstudieswithcompleteor
partial funding from industry and studies funded by
government and other funders (table 3).
Table 3 |Analysis of relation between journal impact factor, citation index factor, study sample size, publication delay, methodological quality, take home
message content, concordance, and source of funding
Is there a relation between: Statistical tests* Interpretation
Sensitivity
analysis carried
out? If yes, what were results?
Methodological quality and JIF (with
aggregate moderate and high risk of
bias studies)?
z=1.3, P=0.184 No evidence of difference in mean JIF between studies with low risk of
bias and studies with (high or moderate) risk of bias
No —
Methodological quality and CIF (with
aggregate moderate and high risk of
bias studies)?
z=−0.19, P=0.851 No evidence of difference in mean CIF between studies with low risk of
bias and studies with (high or moderate) risk of bias
No —
Methodological quality and CSS
(with aggregate moderate and high
risk of bias studies)?
z=−0.96, P=0.338 No evidence of difference in mean CSS between studieswith low risk of
bias and studies with (high or moderate) risk of bias
Yes(onlywithRCT) No change in interpretation
Methodological quality and PD (with
aggregate moderate and high risk of
bias studies)?
z=−0.38, P=0.707 No evidence of difference in mean PD between studies with low risk of
bias and studies with (high or moderate) risk of bias
No —
Take home message and JIF? z=−1.51, P=0.131 No evidence of difference in mean JIF between studies with favourable
take home message and studies with mixed/unfavourable take home
message
No —
Take home message and CIF? z=−1.84, P=0.065 No evidence of difference in mean CIF between studies with favourable
take home message and studies with mixed/unfavourable take home
message
No —
Take home message and CSS? z=−0.41, P=0.682 NoevidenceofdifferenceinmeanCSSbetweenstudieswithfavourable
take home message and studies with mixed/unfavourable take home
message
Yes(onlywithRCT) No change in interpretation
Take home message and PD? z=−0.89 P=0.375 No evidence of difference in mean PD between studies with favourable
take home message and studies with mixed/unfavourable take home
message
No —
Concordance between data
presented and conclusions reported
and JIF?
z=1.1, P=0.273 NoevidenceofdifferenceinmeanJIFbetweenstudieswithconcordance
(yes) and studies with concordance (no/part/unclear)
No —
Concordance between data
presented and conclusions reported
and CIF?
z=0.35 P=0.729 NoevidenceofdifferenceinmeanCIFbetweenstudieswithconcordance
(yes) and studies with concordance (no/part/unclear)
No —
Concordance between data
presented and conclusions reported
and CSS?
z=0.84, P=0.404 No evidence of difference in mean CSS between studies with
concordance (yes) and studies with concordance (no/part/unclear)
Yes(onlywithRCT) No change in interpretation
Concordance between data
presented and conclusions reported
and PD?
z=−0.58, P=0.563 NoevidenceofdifferenceinmeanPDbetweenstudieswithconcordance
(yes) and studies with concordance (no/part/unclear)
——
Funding source and JIF? χ
2=27.4, df=2, P<0.001 EvidenceofdifferenceinmeanJIFbetweenstudieswithindustryfunding
sourceandotherfundingsource.MeanJIFsignificantlygreaterinindustry
funded studies than studies with other funding source
Excluding studies
with undeclared
funding
No change in interpretation
Funding source and CIF? χ
2=13.5, df=2, P<0.001 EvidenceofdifferenceinmeanCIFbetweenstudieswithindustryfunding
source and other funding source. Mean CIF significantly greater in
industry funded studies than studies with other funding source
Excluding studies
with undeclared
funding
Change in interpretation: “no
evidence”
Funding source and CSS? χ
2=0.06, df=2, P=0.997 NoevidenceofdifferenceinmeanCSSbetweenindustryfundedstudies
and government funded studies
Excluding studies
with undeclared
funding and only
with RCT
No change in interpretation
Funding source and PD? χ
2=0.97, df=2, P=0.616 No evidence of difference in mean PD between industry funded studies
and government funded studies
Excluding studies
with undeclared
funding
No change in interpretation
JIF=journal impact factor; CIF=citation index factor; RCT=randomised controlled trial; CSS=comparator sample size; PD=publication delay (difference between publication year and end of
study).
*Kruskal Wallis (χ
2) or Wilcoxon (z).
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sample size of comparator and study design, metho-
dological quality, concordance, and take home mes-
sage.
We conclude that study size is an unlikely explana-
tion for the association between industry sponsorship
and publication in journals with higher impact factors
and that industry funding is associated with a higher
probability of publication in journals with a higher
impact factor and possibly a higher citation index.
The differences in impact factor means between
studies funded by government and those funded by
industry or mixed sponsors were significant and
sufficiently robust. Whole or part industrial funding
wasassociatedwithpublicationinjournalswithhigher
impact factors.
DISCUSSION
In the studies we included, poor methodological
quality was associated with a discrepancy between
resultsand conclusions,and thisin turn wasassociated
with optimistic conclusions in non-government spon-
sored studies. We found no direct association between
thesefindingsandindustryfunding,butthismighthave
been affected by the sizeable number of studies with
undeclared sponsors (23%).
Studies partly or completely sponsored by industry,
however, were published in more prestigious journals
and are probably cited more, although their methodo-
logical quality and size were similar. Some of these
findings might help to explain the continuation of a
near global policy, despite growing doubts as to its
scientific basis.
We reasoned that the combined impact factor and
citation index would give us a good idea of the
circulation and dissemination of the study (that is, the
interest its publication generated). Most of our studies
(70%) were of poor quality with overoptimistic
conclusions—that is, not supported by the data
presented. Those sponsored by industry had greater
visibility as they were more likely to be published by
high impact factor journals and were likely to be given
higher prominence by the international scientific and
lay media, despite their apparent equivalent methodo-
logical quality and size compared with studies with
other funders. Although differences in citation index
by study funding are sensitive to the inclusion of the
large number of studies with undeclared sources of
funding,thehigherimpactfactorandcitationindexare
probably a reflection of a higher profile of industry
sponsored studies and a more thorough dissemination
of their content.
There are two possible mechanisms involved.
Firstly,thesamestudiesarecitedmorethantheothers,
possibly because of the systematic nature of the
dissemination of their results by industry. We have
personally observed this on three recent occasions in
which industry representatives presented abstracts or
reprints of industry sponsored influenza vaccine
studies to decision makers, their advisors, and local
researchers in an effort to influence their decisions.
Symposiums, conferences, and other types of publica-
tion further enhance the dissemination process. Often
the abstracts were expensively bound and translated
into the local language, a tangible sign of their
importance to industry.
We cannot say for certain why industry sponsored
studiesaremoreattractivetomoreprestigiousjournals,
but such journals are preferentially targeted by all
studies because of their prominence and prestige, so
industry sponsored studies might have a higher
probability of acceptance. The two mechanisms
might be linked, but further research, especially in
other specialties, is required. As a measure of
transparency for readers and authors, however, we
recommend that once a year editors and publishers
shouldpostallsourcesofincomerelatedtotherunning
of the journal.
Our finding of lack of concordance between results
and conclusions is similar to those of Yank and
colleagues in an industry sponsored meta-analysis of
antihypertensive drugs.
11 In our studies, however, we
found a lack of concordance between results and
conclusions associated with poor quality rather than
any specific sponsorship. Given our findings of lack of
concordancein primarystudies,the contentof current
policy might reflect the gap between results and
conclusions—that is, synthesis of evidence for policy
makingmightbecarriedoutattwoindependentlevels:
that of results and that of conclusions. In most cases,
what you see is not necessarily what you get.
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